Skip to main content

Table 1 Preoperative characteristics of diabetics and non-diabetics who received intracameral ICMA or a topical regimen for cataract surgery (ITT set)

From: Safety and efficacy of a standardized intracameral combination of mydriatics and anesthetic for cataract surgery in type-2 diabetic patients

 

Diabetics

Non-Diabetics

ICMA Group (N = 24)

Topical Group (N = 33)

ICMA Group (N = 271)

Topical Group (N = 263)

Gender

 Male, n (%)

15 (62.5)

18 (54.5)

105 (38.7)

116 (44.1)

 Female, n (%)

9 (37.5)

15 (45.5)

166 (61.3)

147 (55.9)

Age (years)

 n

24

31

251

255

 Mean ± SD

70.4 ± 9.2

72.2 ± 8.0

69.1 ± 9.5

70.4 ± 9.3

 Min – Max

48–85

52–84

43–87

34–88

Time since cataract diagnosis (months)

 n

24

31

252

255

 Median

4.2

2.8

4.3

4.2

 Min – Max

0.3–134.7

0.2–57.5

0.0–636.6

0.0–111.9

Visible iris diameter at selection (mm)

 n

23

32

263

255

 Mean ± SD

11.5 ± 0.4

11. 8 ± 0.5

11. 9 ± 0.6

11.9 ± 0.5

 Min – Max

10.9–12.5

10.7–12.7

10.0–14.0

10.0–13.5

  1. SD standard deviation, n number of patients, Min minimum, Max maximum, ICMA Group = patients who received an intracameral injection of a standardized combination of 1% lidocaine, 0.02% tropicamide, and 0.31% phenylephrine immediately after the 1st corneal incision; Topical Group = patients who received a topical regimen of 1 drop each of 10% phenylephrine and 0.5% tropicamide